Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70


Standardized Semi-structured Psychosocial Evaluation before Hematopoietic Stem Cell Transplantation Predicts Patient Adherence to Post-Transplant Regimen.

Mishkin AD, Shapiro PA, Reshef R, Lopez-Pintado S, Mapara MY.

Biol Blood Marrow Transplant. 2019 Jun 24. pii: S1083-8791(19)30402-1. doi: 10.1016/j.bbmt.2019.06.019. [Epub ahead of print]


Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation.

Liu A, Li S, Donnenberg V, Fu J, Gollin SM, Ma H, Lu C, Stolz DB, Mapara MY, Monaghan SA, Lentzsch S.

Haematologica. 2018 Oct;103(10):1688-1697. doi: 10.3324/haematol.2018.188227. Epub 2018 Jun 28.


Iatrogenic Infertility After Curative Stem Cell Transplantation in Patients With Sickle Cell Disease.

Mishkin AD, Mapara MY, Reshef R.

Ann Intern Med. 2018 Jun 19;168(12):881-882. doi: 10.7326/M18-0185. Epub 2018 May 1. No abstract available.


CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.

Jin CH, Li Y, Xia J, Li Y, Chen M, Hu Z, Mapara MY, Li W, Yang YG.

Am J Hematol. 2018 Jun;93(6):786-793. doi: 10.1002/ajh.25099. Epub 2018 Apr 16.


IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation.

Li S, Fu J, Wang H, Ma H, Xu X, Yang YG, Deng S, Mapara MY, Lentzsch S.

Blood Adv. 2018 Mar 13;2(5):492-504. doi: 10.1182/bloodadvances.2017010348.


Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.

Kalac M, Lue JK, Lichtenstein E, Turenne I, Rojas C, Amengual JE, Sawas A, Deng C, Mapara MY, Connors JM, Kuruvilla J, O'Connor OA.

Br J Haematol. 2018 Mar;180(5):757-760. doi: 10.1111/bjh.14449. Epub 2016 Dec 16. No abstract available.


Histopathology of Graft-vs-Host Disease of Gastrointestinal Tract and Liver:  An Update.

Salomao M, Dorritie K, Mapara MY, Sepulveda A.

Am J Clin Pathol. 2016 May;145(5):591-603. doi: 10.1093/ajcp/aqw050. Review.


Filgrastim-Induced Crescentic Transformation of Recurrent IgG2λ GN.

Batal I, Markowitz GS, Wong W, Avasare R, Mapara MY, Appel GB, D'Agati VD.

J Am Soc Nephrol. 2016 Jul;27(7):1911-5. doi: 10.1681/ASN.2016010061. Epub 2016 May 4.


Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.

Fu J, Li S, Feng R, Ma H, Sabeh F, Roodman GD, Wang J, Robinson S, Guo XE, Lund T, Normolle D, Mapara MY, Weiss SJ, Lentzsch S.

J Clin Invest. 2016 May 2;126(5):1759-72. doi: 10.1172/JCI80276. Epub 2016 Apr 4.


Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.

Li S, Fu J, Lu C, Mapara MY, Raza S, Hengst U, Lentzsch S.

Mol Cancer Ther. 2016 Apr;15(4):711-9. doi: 10.1158/1535-7163.MCT-15-0798. Epub 2016 Mar 3.


Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.

Ganjoo KN, de Vos S, Pohlman BL, Flinn IW, Forero-Torres A, Enas NH, Cronier DM, Dang NH, Foon KA, Carpenter SP, Slapak CA, Link BK, Smith MR, Mapara MY, Wooldridge JE.

Leuk Lymphoma. 2015 Jan;56(1):42-8. doi: 10.3109/10428194.2014.911859. Epub 2014 Jul 14.


Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.

Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P.

Lancet Oncol. 2014 Jan;15(1):87-95. doi: 10.1016/S1470-2045(13)70512-6. Epub 2013 Nov 30.


Reprogramming donor T cells for adoptive immunotherapy.

Mapara MY.

Immunotherapy. 2013 Dec;5(12):1287-9. doi: 10.2217/imt.13.139. No abstract available.


IL-12hi rapamycin-conditioned dendritic cells mediate IFN-γ-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease.

Stenger EO, Rosborough BR, Mathews LR, Ma H, Mapara MY, Thomson AW, Turnquist HR.

Biol Blood Marrow Transplant. 2014 Feb;20(2):192-201. doi: 10.1016/j.bbmt.2013.11.007. Epub 2013 Nov 12.


Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI.

J Clin Oncol. 2013 Nov 20;31(33):4199-206. doi: 10.1200/JCO.2012.48.3685. Epub 2013 Oct 14.


The quest for the optimal conditioning regimen: some answers, more questions.

Mapara MY.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1275-6. doi: 10.1016/j.bbmt.2013.07.011. Epub 2013 Jul 25. No abstract available.


Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Monaghan SA, Dai L, Mapara MY, Normolle DP, Gollin SM, Lentzsch S.

Leuk Lymphoma. 2013 Sep;54(9):1965-74. doi: 10.3109/10428194.2012.755177. Epub 2013 Jan 28.


Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization.

Li S, Fu J, Ma H, Mapara MY, Lentzsch S.

Leukemia. 2013 Jun;27(6):1407-11. doi: 10.1038/leu.2012.323. Epub 2012 Nov 9. No abstract available.


PDLIM2 restricts Th1 and Th17 differentiation and prevents autoimmune disease.

Qu Z, Fu J, Ma H, Zhou J, Jin M, Mapara MY, Grusby MJ, Xiao G.

Cell Biosci. 2012 Jun 25;2(1):23. doi: 10.1186/2045-3701-2-23.


Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA.

Blood. 2012 May 17;119(20):4608-13. doi: 10.1182/blood-2011-12-395715. Epub 2012 Mar 26.


Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Stenger EO, Turnquist HR, Mapara MY, Thomson AW.

Blood. 2012 May 31;119(22):5088-103. doi: 10.1182/blood-2011-11-364091. Epub 2012 Mar 7. Review.


Targeting the microtubular network as a new antimyeloma strategy.

Feng R, Li S, Lu C, Andreas C, Stolz DB, Mapara MY, Lentzsch S.

Mol Cancer Ther. 2011 Oct;10(10):1886-96. doi: 10.1158/1535-7163.MCT-11-0234. Epub 2011 Aug 8.


Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, Lentzsch S, Mapara MY.

J Clin Invest. 2011 Jul;121(7):2554-69. doi: 10.1172/JCI43706. Epub 2011 Jun 13.


Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.

Ma HH, Ziegler J, Li C, Sepulveda A, Bedeir A, Grandis J, Lentzsch S, Mapara MY.

Cell Immunol. 2011;268(1):37-46. doi: 10.1016/j.cellimm.2011.01.008. Epub 2011 Feb 4.


Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication.

Randhawa PS, Farasati NA, Huang Y, Mapara MY, Shapiro R.

Am J Clin Pathol. 2010 Dec;134(6):916-20. doi: 10.1309/AJCP7JYHJN1PGQVC.


Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.

Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, Ragni MV, Moscinski L, List A, Lentzsch S.

Blood. 2010 Jan 21;115(3):605-14. doi: 10.1182/blood-2009-05-221077. Epub 2009 Nov 25.


C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.

Pal R, Janz M, Galson DL, Gries M, Li S, Jöhrens K, Anagnostopoulos I, Dörken B, Mapara MY, Borghesi L, Kardava L, Roodman GD, Milcarek C, Lentzsch S.

Blood. 2009 Oct 29;114(18):3890-8. doi: 10.1182/blood-2009-01-201111. Epub 2009 Aug 28.


Osteopetrosis with micro-lacunar resorption because of defective integrin organization.

Blair HC, Yaroslavskiy BB, Robinson LJ, Mapara MY, Pangrazio A, Guo L, Chen K, Vezzoni P, Tolar J, Orchard PJ.

Lab Invest. 2009 Sep;89(9):1007-17. doi: 10.1038/labinvest.2009.58. Epub 2009 Jun 22.


KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.

Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, Hager JH, Lentzsch S.

Mol Cancer Ther. 2008 Jun;7(6):1494-505. doi: 10.1158/1535-7163.MCT-08-0183.


The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.

Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S.

Br J Haematol. 2007 Nov;139(3):385-97.


SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.

Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY, Roodman GD, Lentzsch S.

Blood. 2007 Mar 1;109(5):2130-8. Epub 2006 Nov 9.


Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR.

Mapara MY, Leng C, Kim YM, Bronson R, Lokshin A, Luster A, Sykes M.

Biol Blood Marrow Transplant. 2006 Jun;12(6):623-34.


Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S.

Blood. 2006 Apr 15;107(8):3098-105. Epub 2005 Dec 22.


Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene.

Trappe RU, Riess H, Lippek F, Plotkin M, Schumacher V, Royer-Pokora B, Hildebrandt B, Zuber J, Mapara MY, Oertel S, Dörken B.

J Pediatr Hematol Oncol. 2004 Dec;26(12):820-3.


Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis.

Koh KR, Janz M, Mapara MY, Lemke B, Stirling D, Dörken B, Zenke M, Lentzsch S.

Blood. 2005 May 15;105(10):3833-40. Epub 2004 Aug 3.


Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.

Massenkeil G, Roigas J, Nagy M, Wille A, Stroszczynski C, Mapara MY, Loening S, Dörken B, Arnold R.

Bone Marrow Transplant. 2004 Aug;34(4):309-16.


Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.

Mapara MY, Sykes M.

J Clin Oncol. 2004 Mar 15;22(6):1136-51. Review.


Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.

Kim YM, Mapara MY, Down JD, Johnson KW, Boisgerault F, Akiyama Y, Benichou G, Pelot M, Zhao G, Sykes M.

Blood. 2004 Jan 15;103(2):732-9. Epub 2003 Sep 25.


Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.

Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY.

Cancer Res. 2000 Dec 15;60(24):7170-6.


Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.

Reiser M, Josting A, Draube A, Mapara MY, Scheid C, Chemnitz J, Tesch H, Wolf J, Diehl V, Söhngen D, Engert A.

Bone Marrow Transplant. 1999 Jun;23(12):1223-8.


Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study.

Mapara MY, Körner IJ, Lentzsch S, Krahl D, Reichardt P, Dörken B.

Exp Hematol. 1999 Jan;27(1):169-75.


Supplemental Content

Loading ...
Support Center